Caroline Robert

Caroline Robert

Département De Médecine Oncologique, Faculté De Médecine, Gustave Roussy, Service De Dermatologie Et Université Paris-Sud, Paris, France

Direct Impact

Concepts for which Caroline Robert has direct influence:

advanced melanoma
immune checkpoint inhibitors
braf v600
progression-free survival
ctla-4 blockade
phase iii
3 trial

External impact

Concepts related to the work of other authors for which Caroline Robert has influence:

metastatic melanoma
elevated ldh
brain metastases
braf v600
immune checkpoint inhibitors
sentinel node
pd-l1 expression

Prominent publications by Caroline Robert

KOL-Index: 136 Many side-effects of drugs on the nails are now well known. Some are classic while others have been recently described. Since the last edition of this book, antineoplastic drugs have been recognized as affecting the nails. Many nail signs have been described with these treatments, including onycholysis, hematomas, perionyxis and pyogenic granuloma. The severity of the discomfort can sometime ...
Known for
Reverse Transcriptase Inhibitor Therapy | Perionyxis Pyogenic Granuloma | Hematomas | Drugs Effects
KOL-Index: 126 Accumulating evidence suggests that a high tumour burden has a negative effect on anticancer immunity. The concept of tumour burden, simply defined as the total amount of cancer in the body, in contrast to molecular tumour burden, is often poorly understood by the wider medical community; nonetheless, a possible role exists in defining the optimal treatment strategy for many patients. ...
Known for
Markers Circulating | Cancer Tumour
KOL-Index: 116 IntroductionImmuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies being approved across multiple tumor types, it is essential to define unique clinical hallmarks of ...
Known for
Icis Imars | Discontinuing | Responses Improved | Oncology Assessments
KOL-Index: 95 Forty to 60% of patients with advanced or metastatic melanoma respond to first-line immune checkpoint inhibitors (ICI) and half of all patients in the metastatic setting eventually progress. This review evaluated the latest long-term data from clinical trials. It also considered data from recent retrospective studies, as these address important questions for clinical practice. 'Retreatment' ...
Known for
Advanced Metastatic Melanoma Respond | First-Line Immune Checkpoint Inhibitors | Higher Response Rates | Rechallenge Retreatment
KOL-Index: 87 Systemic immunotherapies such as immune checkpoint blockade targeted at PD(L)1 and CTLA4 have demonstrated their ability to provide durable tumor responses and long-term overall survival benefits for some patients in several solid tumor types. However, a majority of patients remain resistant to these treatments and a significant proportion of them develop severe autoimmune and inflammatory ...
Known for
Local Therapeutic | Immunity Tumors | Immunotherapy Strategies | Improve Long
KOL-Index: 78 Translational control of mRNAs during gene expression allows cells to promptly and dynamically adapt to a variety of stimuli, including in neoplasia in response to aberrant oncogenic signalling (for example, PI3K–AKT–mTOR, RAS–MAPK and MYC) and microenvironmental stress such as low oxygen and nutrient supply. Such translational rewiring allows rapid, specific changes in the cell proteome ...
Known for
Resistance Translational | Translation Highlight | Response Aberrant | Therapies Plasticity
KOL-Index: 77 AIMS: Chronic kidney disease (CKD) is an independent risk factor for the development of coronary artery disease (CAD). For both, CKD and CAD, the intercellular transfer of microRNAs (miRs) through extracellular vesicles (EVs) is an important factor of disease development. Whether the combination of CAD and CKD affects endothelial function through cellular crosstalk of EV-incorporated miRs is ...
Known for
Ckd Induced | Compared Evs | Hcaec Derived | Treated Endothelial
KOL-Index: 68 PURPOSE: Although patients with unresectable or metastatic melanoma can experience long-term survival with BRAF- and MEK-targeted agents or immune checkpoint inhibitors over 5 years, resistance develops in most patients. There is a distinct lack of pretherapeutic biomarkers to identify which patients are likely to benefit from each therapy type. Most research has focused on the predictive ...
Known for
Role Tumor | Survival Reached | Serve Potential
KOL-Index: 65 Cutaneous melanoma is associated with strong prognostic phenotypic features such as gender, Breslow’s thickness, and ulceration although the biological significance of these variables is largely unknown. It is likely that these features are surrogates of important biological events rather than promoting directly melanoma progression. High-throughput expression studies have helped deciphering ...
Known for
Phenotypic Melanoma | Braf Therapy | Variables Continuous | Pathway Activated
KOL-Index: 64 Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations ...
Known for
Technical Injection Options | Cancer Tissue | Intratumoral Drug Concentration | Immunotherapy Hit

Département de Médecine Oncologique, Faculté de Médecine, Gustave Roussy, Service de Dermatologie et Université Paris-Sud, Paris, France

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172